Overall ? The mission of the San Diego Center for AIDS Research (SD CFAR) is to find a cure for HIV for those already infected, and to prevent HIV transmission to those not infected. Our Center?s research priorities are aligned with the NIH Office of AID Research priorities and include: optimizing HIV care, alleviating HIV health disparities and advancing scientific discovery for HIV cure and vaccine efforts.
The specific aims of the SD CFAR are to: 1. Foster innovative HIV research by providing the foundation and framework for highly productive collaborations across disciplines, investigators, member institutions, and the HIV community. 2. Capitalize on our community engagement and international expertise to develop sustainable research programs locally and in targeted low and middle income countries highly impacted by HIV. 3. Provide Training, Inspiration, Mentoring, and Expert guidance (TIME) to local and international investigators across career stages. 4. Thoughtfully plan our Center?s growth and flexibility to adapt to an ever evolving research environment. Structure: The SD CFAR is multi-institutional, with members at La Jolla Institute of Allergy and Immunology (LJI), Sanford Burnham Prebys Medical Discovery Institute (SBP), The Scripps Research Institute (TSRI), and University of California San Diego (UCSD). The Center is co-directed by members of our Operations Team including Drs. Davey Smith (contact PI), Douglas Richman, Robert Schooley, and Bruce Torbett. Our CFAR is comprised of ten Cores and one Scientific Working Group. One of these Cores, the Disparities Core, is completely funded by the California HIV Research Program, but remains ingrained as a standalone Core in our Center. We continue to be guided by our External Advisory and Executive Committees, as well as our Co- Directors, Core Directors, Scientific Working Groups and our membership. Progress: Since our renewal in 2012, these efforts have yielded a productive, enthusiastic and growing group of investigators. As the synergy among our investigators and member institutions increases, we have identified the need to expand our infrastructure to address new opportunities. This success has culminated in our move from a Tier 2 to Tier 3 CFAR.

Public Health Relevance

Overall - The SD CFAR supports basic, clinical, behavioral and translational research programs across our member institutions. These activities add considerable value to NIH funded HIV research. In addition to our active, productive and groundbreaking research, we have a remarkable program for fostering the development of emerging investigators, including scientists new to HIV research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-25
Application #
9674207
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
1997-04-01
Project End
2023-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
25
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hoenigl, Martin; Orasch, Thomas; Faserl, Klaus et al. (2018) Triacetylfusarinine C: A urine biomarker for diagnosis of invasive aspergillosis. J Infect :
Howe, Chanelle J; Dulin-Keita, Akilah; Cole, Stephen R et al. (2018) Evaluating the Population Impact on Racial/Ethnic Disparities in HIV in Adulthood of Intervening on Specific Targets: A Conceptual and Methodological Framework. Am J Epidemiol 187:316-325
Arredondo, J; Gaines, T; Manian, S et al. (2018) The law on the streets: Evaluating the impact of Mexico's drug decriminalization reform on drug possession arrests in Tijuana, Mexico. Int J Drug Policy 54:1-8
Ward, Zoe; Platt, Lucy; Sweeney, Sedona et al. (2018) Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? Addiction :
Moore, David J; Jain, Sonia; Dubé, Michael P et al. (2018) Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study. Clin Infect Dis 66:1566-1572
Bortell, Nikki; Basova, Liana; Najera, Julia A et al. (2018) Sirtuin 1-Chromatin-Binding Dynamics Points to a Common Mechanism Regulating Inflammatory Targets in SIV Infection and in the Aging Brain. J Neuroimmune Pharmacol 13:163-178
Pines, H A; Strathdee, S A; Hendrix, C W et al. (2018) Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region. Int J STD AIDS :956462418793038
Burlacu, Ruxandra; Umlauf, Anya; Luca, Anca et al. (2018) Sex-based differences in neurocognitive functioning in HIV-infected young adults. AIDS 32:217-225
Cachay, Edward R; Agmas, Wollelaw; Christopher Mathews, Wm (2018) Disparities in the Clinical Evolution of Anal Neoplasia in an HIV-Infected Cohort. J Racial Ethn Health Disparities 5:209-212
Pines, Heather A; Semple, Shirley J; Strathdee, Steffanie A et al. (2018) Vaginal washing and lubrication among female sex workers in the Mexico-US border region: implications for the development of vaginal PrEP for HIV prevention. BMC Public Health 18:1009

Showing the most recent 10 out of 921 publications